加载中
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
常规交易时段
US$12.595
−US$0.04 · -0.32%
盘中时间采用ET。市场数据可能有所延迟。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日内区间
当前US$12.595
52周区间
当前US$12.595
盘中时间采用ET。市场数据可能有所延迟。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日内区间
当前US$12.595
52周区间
当前US$12.595
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7512.8万 USD | 2883.3万 USD | 3802.5万 USD | 4.85亿 USD | 3.75亿 USD |
| 销货成本 | 2882.1万 USD | — | — | 6643.6万 USD | 4551.6万 USD |
| 毛利 | 4630.7万 USD | 2883.3万 USD | 3802.5万 USD | 4.19亿 USD | 3.3亿 USD |
| 研究与开发 | 1.87亿 USD | 1.67亿 USD | 1.76亿 USD | 1.08亿 USD | 6206.2万 USD |
| 销售、一般及管理费用 | 7658.1万 USD | 8549万 USD | 7517.9万 USD | 6675.5万 USD | 4876.1万 USD |
| 营业费用 | 2.63亿 USD | 3.44亿 USD | 2.75亿 USD | 2.02亿 USD | 1.25亿 USD |
| 利息收入 | 2832.9万 USD | 3847.3万 USD | 4224.7万 USD | 1607.9万 USD | 333万 USD |
| 利息支出 | — | — | — | 404.5万 USD | 522.5万 USD |
| 折旧和摊销 | 2882.1万 USD | 9699.8万 USD | 3089.4万 USD | 3310.2万 USD | 1725万 USD |
| 营业利润 | −2.17亿 USD | −3.15亿 USD | −2.37亿 USD | 2.17亿 USD | 2.04亿 USD |
| 净利润 | −1.46亿 USD | −1.63亿 USD | −1.46亿 USD | 1.59亿 USD | 1.53亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.40
上涨空间 22.27%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB2455.71万0.23%108.2亿 USD0.44%US$201.59-1.31%
iShares Genomics Immunology and Healthcare ETFIDNA829.6万2.63%3.15亿 USD0.47%US$40.92-1.54%
State Street SPDR Portfolio Developed World ex-US ETFSPDW717.15万0.02%406.96亿 USD0.03%US$49.655-0.06%
Fidelity Nasdaq Composite Index ETFONEQ109.06万0.01%109.4亿 USD0.21%US$107.13-0.21%
Avantis U.S. Equity ETFAVUS81.31万0.01%148.68亿 USD0.15%US$130.4-0.11%
Virtus Biotech Clinical Trials ETFBBC75.97万1.81%4191.31万 USD0.65%US$41.7699-2.99%
Avantis U.S. Small Cap Equity ETFAVSC49.75万0.02%30.79亿 USD0.25%US$69.87-0.14%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN37.5万0.11%3.47亿 USD0.47%US$45.755+0.63%iShares Biotechnology ETFIBBiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Nasdaq Composite Index ETFONEQAvantis U.S. Equity ETFAVUSVirtus Biotech Clinical Trials ETFBBCAvantis U.S. Small Cap Equity ETFAVSCInvesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
